Report Overview

The global polycystic kidney disease is expected to grow at CAGR of 4.3% during the forecast period of 2019-2028

Polycystic kidney disease market is expected to gain market growth in the forecast period of 2019 to 2028. The market is growing with the healthy CAGR in the above-mentioned research forecast period. Rising prevalence of serious kidney problems worldwide and emerging markets are the factors responsible for the growth of this market.



Market Growth Drivers

Growing cases of kidney failure or dialysis drives the polycystic kidney disease market. Several reasons can cause polycystic kidney disease such as family history of kidney disorders, rarely genetic mutation, kidney failure or patients on dialysis will also boost up the polycystic kidney disease market. However, rising prevalence of kidney disorders and increased advancement in the diagnosis or treatment of polycystic kidney disease will also enhance the polycystic kidney disease market. Furthermore, awareness in developing countries and last symptoms of the disease may hamper the polycystic kidney disease market

Polycystic Kidney Disease by Type

The global polycystic kidney disease is segmented on the basis of type are Autosomal Dominant Polycystic Kidney Disease (ADPKD), Autosomal Recessive Polycystic Kidney Disease (ARPKD) and others. ADPKD held the largest global PKD drugs market share in 2019. It will remain the leading market shareholder in 2024. ADPKD is the most common form of PKD and increasing prevalence across the world. Therefore, the drug development pipeline mostly contains therapeutic candidates for the treatment of ADPKD. This, coupled with the recent approvals, and special drug designations will drive the growth of the market segment during the forecast period